Dr. Freedland reflects on CARD study of cabazitaxel in mCRPC
Stephen J. Freedland, MD, recaps the findings of the pivotal CARD trial, which compared cabazitaxel (Jevtana) with an androgen receptor pathway inhibitor (ARPI; abiraterone acetate [Zytiga] or enzalutamide [Xtandi]) in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel who had progressed within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide).
Freedland is director of the Center for Integrated Research in Cancer and Lifestyle, co-director of the Cancer Genetics and Prevention Program and associate director for faculty development at the Cancer Institute. He is a faculty physician in the Division of Urology at the Cedars-Sinai Surgery Department.
Freedland is a speaker and consultant for Jevtana developer Sanofi, as well as several other pharmaceutical companies.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.
